Who founded Eikonizo Therapeutics?

Eikonizo Therapeutics was founded by Janice Kranz, PhD in 2017.

Who are Eikonizo Therapeutics's investors?

Eikonizo Therapeutics's investors include Mission Biocapital.

How much funding has Eikonizo Therapeutics raised?

Eikonizo Therapeutics has disclosed $2.4M raised across 2 rounds.

Where is Eikonizo Therapeutics headquartered?

Eikonizo Therapeutics is headquartered in Beverly, US.

Eikonizo Therapeutics

Beverly, US · Founded 2017 · Delaware corporation · 13 employees on LinkedIn · 1 known investors

Eikonizo develops small molecule therapeutics targeting neurodegenerative and cardiorenal diseases. The company is focused on creating novel, disease-modifying treatments to improve patient outcomes.

AI & Machine Learning Biotech Deep Tech Healthtech Medical Devices

Founders & leadership

Eikonizo Therapeutics was founded in 2017 by Janice Kranz, PhD.

Janice Kranz, PhDinFounder

William ShawNamed on SEC filing

Stacie WeningerNamed on SEC filing

Janice KranzNamed on SEC filing

Board

Kevin KinsellaBoard director

Investors · 1

Mission BiocapitalSan Francisco · $500K

Reported raises · per SEC filings

Form D private placements

$2.4M disclosed across 2 rounds · 2018

▶$371.4KraisedMay 2018 · 1 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Janice KranzExecutive Officer, Director
Stacie WeningerDirector
William ShawExecutive Officer, Director
Kevin KinsellaDirector

Offering amount: $841.1K
Amount sold: $371.4K
First sale: May 2018
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2MraisedApr 2018 · 2 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

William ShawExecutive Officer, Director
Kevin KinsellaDirector
Stacie WeningerDirector
Janice KranzExecutive Officer, Director

Offering amount: $2M
Amount sold: $2M
First sale: Mar 2018
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Actio Biosciences, Inc.3 shared keywordsActio is a precision medicine company that translates genetic insights into new therapeutics, developing drugs that target the genes underlying both rare diseases and more prevalent conditions. It focuses on identifying dysregulated gene activity and designing therapies to restore balance and address the root causes of disease.

Companies competing with Eikonizo Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Eikonizo Therapeutics Receives Equity Investment From Novo Nordiskfinsmes.com · Dec 2024

Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate EKZ-102 Toward Clinical Developmentfinance.yahoo.com · Dec 2024

Eikonizo Therapeutics, Inc. announced that it has received funding from Novo Nordisk A/S | MarketScreenermarketscreener.com · Dec 2024

Frequently asked questions

What does Eikonizo Therapeutics do?: Eikonizo develops small molecule therapeutics targeting neurodegenerative and cardiorenal diseases. The company is focused on creating novel, disease-modifying treatments to improve patient outcomes.
Who founded Eikonizo Therapeutics?: Eikonizo Therapeutics was founded by Janice Kranz, PhD in 2017.
Who are Eikonizo Therapeutics's investors?: Eikonizo Therapeutics's investors include Mission Biocapital.
How much funding has Eikonizo Therapeutics raised?: Eikonizo Therapeutics has disclosed $2.4M raised across 2 rounds.
Where is Eikonizo Therapeutics headquartered?: Eikonizo Therapeutics is headquartered in Beverly, US.